文献速递糖尿病肥胖与代谢综合征性腺与生殖内分泌

艾塞那肽、达格列净或芬特明/托吡酯对多囊卵巢综合征代谢谱的差异影响

Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该单盲随机对照研究纳入119例肥胖(BMI>30且<45)的非糖尿病多囊卵巢综合征(PCOS)女性,比较每周一次艾塞那肽(EQW)、达格列净(DAPA)单用或联用、DAPA/二甲双胍(MET)及芬特明/托吡酯(PHEN/TPM)治疗24周对代谢参数、体成分和性激素的影响,发现EQW/DAPA在临床和代谢获益上优于其他方案。

要点

  • EQW/DAPA和PHEN/TPM减重、减总脂肪和腰围最显著。
  • 仅EQW/DAPA和EQW显著改善平均血糖、胰岛素敏感性和分泌。
  • 所有药物均降低空腹血糖、睾酮、游离雄激素指数和血压。

核心结论

  • 在肥胖PCOS女性中,EQW/DAPA双联治疗在临床和代谢获益上优于EQW或DAPA单用、DAPA/MET及PHEN/TPM。

研究设计与样本

  • 单盲随机对照研究,纳入119例18-45岁、BMI>30且<45、符合美国国立卫生研究院(NIH)标准的多囊卵巢综合征(PCOS)非糖尿病女性。
  • 随机分配至EQW 2 mg每周一次、DAPA 10 mg每日一次、EQW/DAPA(2 mg每周一次/10 mg每日一次)、DAPA 10 mg/二甲双胍2000 mg缓释每日一次、或PHEN 7.5 mg/TPM 46 mg缓释每日一次,治疗24周。
  • 基线及24周评估体重、血压、腰围、双能X线吸收法(DXA)体成分、口服葡萄糖耐量试验(血糖、平均血糖、胰岛素敏感性和分泌)、性激素、游离雄激素指数(FAI)和血脂。

主要发现

  • EQW/DAPA和PHEN/TPM导致体重、DXA总脂肪和腰围下降最多。
  • 尽管PHEN/TPM与EQW/DAPA在BMI和腰围下降上等效,但仅EQW/DAPA和EQW显著改善平均血糖、胰岛素敏感性和胰岛素分泌。
  • 所有药物均降低空腹血糖、睾酮、FAI和血压。

临床怎么用

  • 对于肥胖PCOS女性,EQW/DAPA双联治疗可能带来更优的临床和代谢获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce weight and improve insulin sensitivity via different mechanisms. OBJECTIVE: The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered (EQW/DAPA), DAPA/extended-release (ER) metformin (DAPA/MET), and phentermine topiramate extended release (PHEN/TPM) on metabolic parameters, body composition, and sex hormones were examined in obese women with PCOS. METHODS: Nondiabetic women (n = 119; aged 18-45 years) with a body mass index (BMI) greater than 30 and less than 45 and polycystic ovary syndrome (National Institutes of Health criteria) were randomly assigned in a single-blinded fashion to EQW (2 mg weekly); DAPA (10 mg daily), EQW/DAPA (2 mg weekly/10 mg daily), DAPA (10 mg)/MET (2000 mg XR daily), or PHEN (7.5 mg)/TPM (46 mg ER daily) treatment for 24 weeks. Study visits at baseline and 24 weeks included weight, blood pressure (BP), waist (WC) measures, and body composition evaluated by dual-energy x-ray absorptiometry (DXA). Oral glucose tolerance tests were conducted to assess glycemia and mean blood glucose (MBG), and compute insulin sensitivity (SI) and secretion (IS) measures. Sex steroids, free androgen index (FAI), and lipid profiles were measured in the fasting sample. RESULTS: EQW/DAPA and PHEN/TPM resulted in the most loss of weight and total body fat by DXA, and WC. Despite equivalent reductions in BMI and WC with PHEN/TPM, only EQW/DAPA and EQW resulted in significant improvements in MBG, SI, and IS. Reductions in fasting glucose, testosterone, FAI, and BP were seen with all drugs. CONCLUSION: Dual therapy with EQW/DAPA was superior to either alone, DAPA/MET and PHEN/TPM in terms of clinical and metabolic benefits in this patient population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Elkind-Hirsch KE, Chappell N, Seidemann E, et al. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021. PMID: 34097062. doi:10.1210/clinem/dgab408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。